SEC Filings
Perceptive Advisors Sold 5.5 Million Nautilus Shares And Slips Below A 5% Stake
Joseph Edelman's fund manager now holds 3.9% of Nautilus Biotechnology after open-market sales that ran from July 28 to October 26.
NAUT
Nautilus Biotechnology (NAUT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Nautilus Eyes A Capital Raise By Mid-2027 As CEO Pitches Proteoforms, Not Gene Count, As The Key To Biology
The protein-analysis company posted $0.2 million of third-quarter revenue and a $15.6 million net loss, with cash lasting into early 2028.
Earnings
Nautilus Eyes A Fundraise Before Mid-2027, Though Cash Lasts Into 2028
The proteomics company reported $0.2 million in third-quarter revenue and $114.3 million in cash, and said it is weighing how to raise funds.
SEC Filings
Nautilus Biotechnology Lines Up A $125 Million Stock-Sale Program With $114.3 Million In Cash Left
The proteomics developer swapped its at-the-market agreement in September and added a $300.0 million shelf, with no shares sold yet.
Earnings
Nautilus Third-Quarter Loss Widens To $15.6 Million With $114.3 Million In Cash And Investments
The pre-product proteomics company's operating costs rose 10%, and it still points to mid-2027 for instrument availability.